Syschem India Ltd. · BSE:SYSCHEM
Syschem India — Investor Presentation (2025)
25 slides from Syschem India's investor presentation, 2025
Slide 1: Investor's Presentation 2025
Investor’s Presentation Presentation 2025
Slide 2: Table Of Contents
Company Overview New Plant Evolution of API Products KEY PRODUCTS Pharmaceutical Strategy Table Of Key Goals Main Areas of Operation Contents Model and Roadmap CAPACITY AND UTILISATION Proven Track Record Financials OUR CLIENTS About Our Team SAFE HARBOR STATEMENT Thank You
Slide 3: Company Overview
Company Overview Syschem (India) Limited (SIL) is a listed company engaged in the manufacturing of Bulk Drugs/Intermediates and contract manufacturing. It is owned and operated by a highly committed group of techno commercial with extensive experience in the bulkdrug business. AGENDA
Slide 4: Committed team of techno-commercial specialists
The Company is committed to its highly committed team of techno-commercial specialists with considerable expertise in the bulk medicine market. Syschem India Limited has established a firm presence in the business by providing their consumers with high-quality products and services. The Company's co
Slide 5: New Plant
NEW PLANT SYSCHEM
Slide 6: The Evolution for API Products
THE EVOLUTION FOR API PRODUCTS AGENDA
Slide 7: Key Products
KEY PRODUCTS AMOXICILLIN AMPICIILLIN A broad-spectrum penicillin 01 antibiotic used to treat bacterial A penicillin antibiotic effective 02 against both gram-positive and infections some gram-negative bacteria. CLOXACILLIN DICLOXACILLIN A penicillinase-resistant penicillin A beta-lactam antibiotic u
Slide 8: Pharmaceutical Strategy
Pharmaceutical Strategy Innovating for Future Success AGENDA
Slide 9: Strategic Vision & Evolution
STRATEGIC VISION & EVOLUTION OUR DIRECTION 1 Largely the capacity expansions 2 Increase in distribution network 3 Adding Product Ranges AGENDA
Slide 10: Our Strategic Vision Explained
Our Strategic Vision Explained SIL's vision is to boost production of our existing products while expanding our offers by creating various intermediates that are now imported from China for the API industry. Over the next 2-3 years, we hope to minimise our reliance on imports and attain more self-su
Slide 11: High Growth Potential & Shareholder Value Creation
HIGH GROWTH POTENTIAL & SHAREHOLDER VALUE CREATION Our company’s rapid growth—fueled by innovation, global expansion, and robust product pipelines— demonstrates our ability to meet rising healthcare demands and successfully enter new markets. This sustained momentum translates into strong shareholde
Slide 12: Year-on-year growth in production
"We aim to drive year-on-year growth in production to meet our strategic objectives." AGENDA
Slide 13: Key Goals
YoY improved quality. Improved market position on YoY basis. Built up new plant of amoxicilin and ampicilin , according to WHO GMP. KEY GOALS Planning to enter in international market with necessary approvals. 2023-25 AGENDA
Slide 14: Main Areas of Operation
Main Areas of Operation The company has a diverse range of intermediate items in the pharmaceuticals industry that are created chemically. The company has established a foothold in India and the international market; its products have been exported to Latin America, Africa, Thailand, Sri Lanka, Nepa
Slide 15: Supply Zone
Main Areas of Operation SUPPLY ZONE 24% Expanding operations and improving customer satisfaction are core goals for any thriving business. As we continue to grow, our focus remains on understanding and anticipating the needs of our customers, ensuring that we deliver unparalleled service and quality
Slide 16: Innovation Roadmap Journey
Innovation Roadmap Journey Business Model Strategic Shift to Performance Current Position Evolution Independent Sales Highlights & Future Outlook Operated under a contract Transitioned from contract Recorded highest-ever topline Built a strong customer base and manufacturing model due to manufacturi
Slide 17: Proven Track Record of Production
PROVEN TRACK RECORD OF PRODUCTION Excellence in Delivery Every Time AGENDA
Slide 18: Proven Track Record of Topline
Proven Track Record of Topline Showcasing consistent growth strategies 2024-25 100% 2023-24 60.5% 2024-25 2023-24 2022-23 33.9% 2022-23 AGENDA 2.1%
Slide 19: Capacity and Utilisation
2022-23 2023-24 2024-25 2000 1500 Capacity and Utlisation 1000 500 CAPACITY AND 0 2022-23 2023-24 FY Utilisation %age 2024-25 UTILISATION 100 80 60 Utilisation %age 40 20 AGENDA 0 2022-23 2023-24 2024-25 FY
Slide 20: Financials
EBIDTA 2022-23 2023-24 2024-25 2024-25 402 2022-23 890 2023-24 715 FINANCIALS AGENDA PBT PAT 700 600 500 400 300 200 100 0 2022-23 2023-24 2024-25
Slide 21: Our Clients
OUR CLIENTS AGENDA m LABORATE Ls " mimalaya SINCE 1930 AAGYA fn Scott S, KA Medico Remedies Ltd
Slide 22: About Our Team
About Our Team The people behind the company's achievements At the heart of our pharmaceutical company lies an exceptional team that embodies innovation, collaboration, and commitment to excellence. Our diverse group of professionals, ranging from "The remarkable expansion in revenue has characteris
Slide 23: Safe Harbor Statement
SAFE HARBOR STATEMENT AGENDA This Information Memorandum has been prepared by the Company based on information and data which the Company considers reliable. However, the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accura
Slide 24: Forward-looking statements
Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known
Slide 25: Thank You
THANK YOU A Presentation by - AGENDA Factory at. : Village Bargodam, Tehsil Kalka, Dist. Panchkula, Haryana-133302 Corp Office. : 825, FF, NAC Manimajra , Chandigarh-161001 Telephone no : 0172-5070471 Email Id : info@syschem.in